- EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
- MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
- EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
- HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
“Client's Success is Our Priority”
EirGenix upholds the mission of providing clients with high-quality and cost-effective CDMO services and biologics. All in order to enhance the wellbeing of individuals and society, and improve the quality of life.
The most experienced technical team will bring the greatest benefits to customers and patients
We hope patients can use affordable high-quality biological drugs
Assist customers to go faster and further on the journey of biotechnology drug development, because successfully developed drugs can bring more protection to human health
Eirgenix was established on December 21, 2012
12 x 2,000 liter single use bioreactors
Annual production of antibodies can reach up to 1,000kg
EirGenix provides comprehensive cell line development services from DNA replication to the generation of stable producer cell lines for further process development and manufacturing.